---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-035914"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T00:45:56.073560+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics: FDA won't hold adcom for aficamten NDA; Late Cycle meeting set for June 2025

## Summary
- Cytokinetics completed midcycle review with FDA for aficamten NDA treating obstructive hypertrophic cardiomyopathy.
- FDA informed Cytokinetics it does not plan to convene an advisory committee meeting for the aficamten NDA.
- Late Cycle meeting with FDA expected in June 2025; company maintains expectation for differentiated label and risk mitigation if approved.
- Cytokinetics does not plan to share detailed updates on FDA communications beyond this update.

## SEC filing metadata
- accession: 0000950170-25-035914
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017025035914/0000950170-25-035914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017025035914/cytk-20250310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-035914
- JSON: https://secwatch.observer/filing/0000950170-25-035914.json
- Plain text: https://secwatch.observer/filing/0000950170-25-035914.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.